66 results on '"González-Romo F"'
Search Results
2. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance
- Author
-
Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J.R., García-Rodríguez, J., Cerrada, C.G., Fortún, J., Martín, P., Gómez, E., Ryan, P., Campelo, C., de los Santos Gil, I., Buendía, V., Gorricho, B.P., Alonso, M., Sanz, F.S., Aguado, J.M., Merino, P., González Romo, F., Gorgolas, M., Gadea, I., Losa, J.E., Delgado-Iribarren, A., Ramos, A., Romero, Y., Romero, I.S., Zaragoza, O., Cuenca-Estrella, M., Rodríguez-Baño, J., Suarez, A.I., Loza, A., Aller García, A.I., Martín-Mazuelos, E., Pérez de Pipaón, M.R., Garnacho, J., Ortiz, C., Chávez, M., Maroto, F.L., Salavert, M., Pemán, J., Blanquer, J., Navarro, D., Camarena, J.J., Zaragoza, R., Abril, V., Gimeno, C., Hernández, S., Ezpeleta, G., Bereciartua, E., Hernández Almaraz, J.L., Montejo, M., Rivas, R.A., Ayarza, R., Planes, A.M., Camps, I.R., Almirante, B., Mensa, J., Almela, M., Gurgui, M., Sánchez-Reus, F., Martínez-Montauti, J., Sierra, M., Horcajada, J.P., Sorli, L., Gómez, J., Gené, A., Urrea, M., Mularoni, A., Valerio, M., Díaz-Martín, A., Puchades, F., Fernández-Ruiz, M., Lora-Pablos, D., Zaragoza, Ó., and Puig-Asensio, M.
- Published
- 2017
- Full Text
- View/download PDF
3. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
- Author
-
Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J.R., García-Rodríguez, J., García Cerrada, C., Fortún, J., Martín, P., Gómez, E., Ryan, P., Campelo, C., de los Santos Gil, I., Buendía, V., Gorricho, B.P., Alonso, M., Sanz, F.S., Aguado, J.M., Merino, P., González Romo, F., Gorgolas, M., Gadea, I., Losa, J.E., Delgado-Iribarren, A., Ramos, A., Romero, Y., Sánchez Romero, I., Zaragoza, O., Cuenca-Estrella, M., Rodriguez-Baño, J., Isabel Suarez, A., Loza, A., Aller García, A.I., Martín-Mazuelos, E., Pérez de Pipaón, M.R., Garnacho, J., Ortiz, C., Chávez, M., Maroto, F.L., Salavert, M., Pemán, J., Blanquer, J., Navarro, D., Camarena, J.J., Zaragoza, R., Abril, V., Gimeno, C., Hernáez, S., Ezpeleta, G., Bereciartua, E., Hernández Almaraz, J.L., Montejo, M., Rivas, R.A., Ayarza, R., Planes, A.M., Camps, I.R., Almirante, B., Mensa, J., Almela, M., Gurgui, M., Sánchez-Reus, F., Martinez-Montauti, J., Sierra, M., Horcajada, J.P., Sorli, L., Gómez, J., Gené, A., Urrea, M., Valerio, M., Díaz-Martín, A., Puchades, F., Mularoni, A., Rueda, C., and Puig-Asensio, M.
- Published
- 2017
- Full Text
- View/download PDF
4. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort
- Author
-
Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J.R., García-Rodríguez, J., García Cerrada, C., Fortún, J., Martín, P., Gómez, E., Ryan, P., Campelo, C., de los Santos Gil, I., Buendía, V., Pérez Gorricho, B., Alonso, M., Sanz Sanz, F., María Aguado, J., Merino, P., González Romo, F., Gorgolas, M., Gadea, I., Losa, J.E., Delgado-Iribarren, A., Ramos, A., Romero, Y., Sánchez Romero, I., Zaragoza, O., Cuenca-Estrella, M., Rodríguez-Baño, J., Suarez, A.I., Loza, A., Aller García, A.I., Martín-Mazuelos, E., Pérez de Pipaón, M.R., Garnacho, J., Ortiz, C., Chávez, M., Maroto, F.L., Salavert, M., Pemán, J., Blanquer, J., Navarro, D., Camarena, J.J., Zaragoza, R., Abril, V., Gimeno, C., Hernáez, S., Ezpeleta, G., Bereciartua, E., Hernández Almaraz, J.L., Montejo, M., Rivas, R.A., Ayarza, R., Planes, A.M., Ruiz Camps, I., Almirante, B., Mensa, J., Almela, M., Gurgui, M., Sánchez-Reus, F., Martinez-Montauti, J., Sierra, M., Horcajada, J.P., Sorli, L., Gómez, J., Gené, A., Urrea, M., Valerio, M., Díaz-Martín, A., Puchades, F., Mularoni, A., López-Cortés, L.E., Garnacho-Montero, J., Puig-Asensio, M., and Ruiz-Camps, I.
- Published
- 2016
- Full Text
- View/download PDF
5. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains
- Author
-
Cuervo, G., Puig-Asensio, M., Garcia-Vidal, C., Fernández-Ruiz, M., Pemán, J., Nucci, M., Aguado, J.M., Salavert, M., González-Romo, F., Guinea, J., Zaragoza, O., Gudiol, C., Carratalà, J., and Almirante, B.
- Published
- 2015
- Full Text
- View/download PDF
6. Monitoring the antimicrobial susceptibility of Gramnegative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017)
- Author
-
Cantón, R., Loza, E., Aznar, J., Castillo, F.J., Cercenado, E., Fraile-Ribot, P.A., González-Romo, F., López-Hontangas, J.L., Rodríguez-Lozano, J., Suárez-Barrenechea, A.I., Tubau, F., Díaz-Regañón, J., López-Mendoza, D., Seral, C., Calvo, J., Domínguez, M.A., Pérez Sáenz, J.L., Oliver, A., García-Castillo, M., Prieto, J., Rodríguez-Rey, A., and Pascual, A.
- Subjects
polycyclic compounds ,bacterial infections and mycoses - Abstract
OBJECTIVE: Continuous antimicrobial resistance surveillance is recommended by Public Health authorities. We up-dated data from the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain. METHODS: The antimicrobial susceptibility data and extended-spectrum beta-lactamase (ESBL) production in isolates recovered from intra-abdominal (IAI) (n=1,429) and urinary tract (UTI) (n=937) infections during the 2016- 2017 SMART study in 10 Spanish hospitals were analysed. RESULTS: Escherichia coli was the most frequently microorganism isolated (48.3% and 53.7%) followed by Klebsiella spp. (11.5% and 21.9%) in IAIs and UTIs, respectively. Figures for Pseudomonas aeruginosa were 9.0% and 6.1%, being more frequently recovered from patients with nosocomial infections. Overall, 9.9% (IAI) and 14.0% (UTI) of E. coli, Klebsiella spp. and Proteus mirabilis isolates were ESBL-producers, being Klebsiella pneumoniae (34.5%) from UTI of nosocomial origin the most frequent. ESBL-producers were higher in patients >60 years in both IAIs and UTIs. As in previous years, amikacin (96.3%-100% susceptibility), ertapenem (84.2%-100%) and imipenem (70.3%- 100%) were the most active antimicrobials tested among Enterobacterales species. The activity of amoxicillin-clavulanic, piperacillin-tazobactam, and ciprofloxacin susceptibility was lower, particularly among ESBL-producers. Ertapenem susceptibility (88.9%-100%) was retained in ESBL-E. coli isolates that were resistant to these antimicrobials but decreased (28.6%-100%) in similar isolates of K. pneumoniae. CONCLUSIONS: Continuous antimicrobial resistance surveillance from the SMART study reveals overall maintenance of ESBL-producers in Spain, although with higher presence in isolates from UTIs than from IAIs. Moreover, ertapenem activity was high in E. coli irrespective of ESBL production but decreased in K. pneumoniae, particularly among ESBL-producers.
- Published
- 2019
7. Seguimiento de la sensibilidad antimicrobiana de microorganismos gramnegativos procedentes de infecciones intraabdominales y urinarias del estudio smart (España, 2016 y 2017)
- Author
-
Cantón R., Loza E., Aznar J., Castillo F.J., Cercenado E., Fraile-Ribot P.A., González-Romo F., López-Hontangas J.L., Rodríguez-Lozano J., Suárez-Barrenechea A.I., Tubau F., Díaz-Regañón J., López-Mendoza D., Calvo J., Domínguez M.A., Pérez Sáenz J.L., Oliver A., Seral C., García-Castillo M., Prieto J., Rodríguez-Rey A., Pascual A., and SMART-Spain Working Group
- Abstract
Introducción. Las autoridades de Salud Pública recomiendan la vigilancia continua de la resistencia a los antimicrobianos. Se actualizan los datos del estudio SMART (Study for Monitoring Antimicrobial Resistance Trends) en España. Material y métodos. Se analizaron los datos de sensibilidad antimicrobiana y la producción de betalactamasas de espectro extendido (BLEE) en aislamientos obtenidos en el estudio SMART de infecciones intraabdominales (IIA) (n=1.429) y del tracto urinario (ITU) (n=937) durante 2016-2017 en 10 hospitales españoles. Resultados. Escherichia coli fue el microorganismo más frecuente (54,5% y 57,5%, respectivamente), seguido de Klebsiella spp. (18,4% y 25,4%) en IIA y en ITU. En Pseudomonas aeruginosa estas cifras fueron 9% y 6%, siendo más frecuente en la infección nosocomial. El 9,9% (IIA) y el 14% (ITU) del total de los aislados de E. coli, Klebsiella spp. y Proteus mirabilis producían BLEE, obteniéndose la tasa más alta en Klebsiella pneumoniae (34.5%) en ITU nosocomial. El mayor porcentaje de aislados con BLEE se observó en pacientes >60 años, tanto en IIA como en ITU. Como en años anteriores, amikacina (sensibilidad 96,3%-100%), ertapenem (84,2%-100%) e imipenem (70,3%-100%) fueron los antimicrobianos más activos en Enterobacterales. La sensibilidad a amoxicilina-ácido clavulánico, piperacilina-tazobactam y ciprofloxacino fue menor, en particular en los productores de BLEE. La sensibilidad a ertapenem (88,9%-100%) se mantuvo en E. coli con BLEE resistente a estos antimicrobianos, pero disminuyó (28,6%-100%) en aislados similares de K. pneumoniae. Conclusiones. La vigilancia continua de la resistencia a los antimicrobianos en el estudio SMART revela el mantenimiento de la frecuencia de aislados productores de BLEE en España, pero con mayor presencia en las ITUs que en las IIAs. Además, la sensibilidad a ertapenem fue alta en E. coli con independencia de la producción de BLEE, pero disminuyó en K. pneumoniae, sobre todo en los productores de BLEE. Introduction. Continuous antimicrobial resistance surveillance is recommended by Public Health authorities. We updated data from the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain. Material and methods. The antimicrobial susceptibility data and extended-spectrum beta-lactamase (ESBL) production in isolates recovered from intra-abdominal (IAI) (n=1,429) and urinary tract (UTI) (n=937) infections during the 2016-2017 SMART study in 10 Spanish hospitals were analysed. Results. Escherichia coli was the most frequently microorganism isolated (48.3% and 53.7%) followed by Klebsiella spp. (11.5% and 21.9%) in IAIs and UTIs, respectively. Figures for Pseudomonas aeruginosa were 9.0% and 6.1%, being more frequently recovered from patients with nosocomial infections. Overall, 9.9% (IAI) and 14.0% (UTI) of E. coli, Klebsiella spp. and Proteus mirabilis isolates were ESBL-producers, being Klebsiella pneumoniae (34.5%) from UTI of nosocomial origin the most frequent. ESBL-producers were higher in patients >60 years in both IAIs and UTIs. As in previous years, amikacin (96.3%-100% susceptibility), ertapenem (84.2%-100%) and imipenem (70.3%-100%) were the most active antimicrobials tested among Enterobacterales species. The activity of amoxicillin-clavulanic, piperacillin-tazobactam, and ciprofloxacin susceptibility was lower, particularly among ESBL-producers. Ertapenem susceptibility (88.9%-100%) was retained in ESBL-E. coli isolates that were resistant to these antimicrobials but decreased (28.6%-100%) in similar isolates of K. pneumoniae. Conclusions. Continuous antimicrobial resistance surveillance from the SMART study reveals overall maintenance of ESBL-producers in Spain, although with higher presence in isolates from UTIs than from IAIs. Moreover, ertapenem activity was high in E. coli irrespective of ESBL production but decreased in K. pneumoniae, particularly among ESBL-producers.
- Published
- 2019
8. Antimicrobial susceptibility trends and evolution of isolates with extended spectrum ß-lactamases among gram-negative organisms recovered during the SMART study in Spain (2011-2015)
- Author
-
Cantón, R., Loza, E., Aznar, J., Barrón-Adúriz, R., Calvo, J., Castillo, F.J., Cercenado, E., Cisterna, R., González-Romo, F., López-Hontangas, J.L., Suárez-Barrenechea, A.I., Tubau, F., Molloy, B., López-Mendoza, D., Herrero, O., Martínez-Martínez, L., Domínguez, M.A., Sáenz, J.L.P., Seral, C., Arcía-Castillo, M., Prieto, J., González-Galán, V., and Pascual, A.
- Abstract
Introducción. El estudio SMART (Study for Monitoring Antimicrobial Resistance Trends) monitoriza la sensibilidad antimicrobiana y las ß-lactamasas de espectro extendido (BLEE) en bacilos gramnegativos obtenidos de infecciones intraabdominales (IIA). Material y Métodos. Se ha analizado la sensibilidad antimicrobiana (microdilución estándar, criterios EUCAST) y las BLEE (detección fenotípica) de 5.343 aislados de IIA en 11 centros del programa SMART-España durante 2011-2015 en comparación con 2002-2010. Resultados. Escherichia coli, el microorganismo más prevalente, disminuyó significativamente en las IIA de origen comunitario (60, 9% 2002-2010 vs. 56, 1% 2011- 2015, P=0, 0003). Fue seguido en prevalencia por Klebsiella pneumoniae que aumentó tanto en IIA comunitaria (8, 9% vs. 10, 8%, P=0, 016) como nosocomial (9, 2% vs. 10, 8%, P=0, 029) y por P. aeruginosa que aumentó en la IIA comunitaria (5, 6% vs. 8, 0%, P=0, 0003). Las BLEE fueron más prevalentes en la IIA nosocomial por K. pneumoniae (16, 3%) que por E. coli (9, 5%), siendo más frecuentes en pacientes de mayor edad (>60 años). Considerando todas las Enterobacteriaceae, ertapenem (92, 3- 100%) y amikacina (95, 5%-100%) fueron los antimicrobianos más activos. La sensibilidad a ertapenem, al contrario que a amoxicilina-clavulánico o piperacilina-tazobactam, se mantuvo sin cambios en E. coli con (98, 8%) y sin BLEE (100%). Su sensibilidad disminuyó en BLEE-K. pneumoniae (74, 7%) pero fue mayor que la de amoxicilina-clavulánico (14, 0%) o piperacilina-tazobactam (24, 0%). Es de resaltar que esta actividad se mantuvo >60% en los aislados con BLEE resistentes a amoxicilina-clavulánico, piperacilina-tazobactam o fluoroquinolonas. Conclusiones. El estudio SMART-España sustenta las guías actuales que incluyen al ertapenem como tratamiento empírico en la IIA leve-moderada comunitaria, en particular con BLEE. Estas recomendaciones precisaran actualizarse con la reciente introducción de nuevos antimicrobianos. Introduction. The SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study monitors antimicrobial susceptibility and extended spectrum ß-lactamases (ESBLs) in Gram-negative bacilli recovered from intra-abdominal infections (IAI). Material and methods. Antimicrobial susceptibility of 5, 343 isolates from IAI recovered in 11 centres during the 2011-2015 SMART-Spain program was analysed by standard microdilution (EUCAST criteria) and compared with that from 2002-2010. ESBLs were phenotypically detected. Results. Escherichia coli, the most common isolate, significantly decreased in community acquired IAI (60.9% 2002-2010 vs. 56.1% 2011-2015, P=0.0003). It was followed in prevalence by Klebsiella pneumoniae that increased both in the community (8.9% vs. 10.8%, P=0.016) and nosocomial (9.2% vs. 10.8%, P=0.029) IAI and P. aeruginosa, which significantly increased in community acquired IAI (5.6% vs. 8.0%, P=0.0003). ESBLs were more prevalent in K. pneumoniae (16.3%) than in E. coli (9.5%) of nosocomial origin and were more frequently isolated from elderly patients (>60 years). Considering all Enterobacteriaceae, ertapenem (92.3-100%) and amikacin (95.5%-100%) were the most active antimicrobials. Ertapenem activity, unlike amoxicillin-clavulanate or piperacillin-tazobactam, remained virtually unchanged in ESBL (100%) and non-ESBL (98.8%) E. coli producers. Its activity decreased in ESBL-K. pneumoniae (74.7%) but was higher than that of amoxicillin-clavulanate (14.0%) and piperacillin-tazobactam (24.0%). Interestingly, ertapenem susceptibility was maintained in >60% of ESBL isolates that were resistant to amoxicillin-clavulanate, piperacillin-tazobactam or fluoroquinolones. Conclusions. SMART-Spain results support current guidelines which include ertapenem as empiric treatment in mild-moderate community-acquired IAI, particularly with ESBL producers. These recommendations will need to be updated with the recently introduction of new antimicrobials.
- Published
- 2018
9. Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among Gram-negative organisms recovered during the SMART study in Spain (2011-2015)
- Author
-
Cantón, R, Loza, E, Aznar, J, Barrón-Adúriz, R, Calvo, J, Castillo, F J, Cercenado, E, Cisterna, R, González-Romo, F, López-Hontangas, J L, Suárez-Barrenechea, A I, Tubau, F, Molloy, B, and López-Mendoza, D
- Subjects
Adult ,Ertapenem ,Male ,Microbial Sensitivity Tests ,beta-Lactams ,beta-Lactamases ,Surveillance study ,β-lactamasas de espectro extendido ,Intra-abdominal infections ,Infección intraabdominal ,Gram-Negative Bacteria ,Escherichia coli ,Prevalence ,Humans ,Aged ,Aged, 80 and over ,Cross Infection ,Middle Aged ,bacterial infections and mycoses ,Anti-Bacterial Agents ,Drug Combinations ,Klebsiella pneumoniae ,Carbapenems ,Spain ,Estudio de vigilancia epidemiológica ,Female ,Gram-Negative Bacterial Infections ,Extended spectrum β-lactamases - Abstract
SMART-Spain Working Group. [Objective] The SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study monitors antimicrobial susceptibility and extended spectrum β-lactamases (ESBLs) in Gram-negative bacilli recovered from intra-abdominal infections (IAI). [Methods] Antimicrobial susceptibility of 5,343 isolates from IAI recovered in 11 centres during the 2011-2015 SMART-Spain program was analysed by standard microdilution (EUCAST criteria) and compared with that from 2002-2010. ESBLs were phenotypically detected. [Results] Escherichia coli, the most common isolate, significantly decreased in community acquired IAI (60.9% 2002-2010 vs. 56.1% 2011-2015, P=0.0003). It was followed in prevalence by Klebsiella pneumoniae that increased both in the community (8.9% vs. 10.8%, P=0.016) and nosocomial (9.2% vs. 10.8%, P=0.029) IAI and P. aeruginosa, which significantly increased in community acquired IAI (5.6% vs. 8.0%, P=0.0003). ESBLs were more prevalent in K. pneumoniae (16.3%) than in E. coli (9.5%) of nosocomial origin and were more frequently isolated from elderly patients (>60 years). Considering all Enterobacteriaceae, ertapenem (92.3-100%) and amikacin (95.5%-100%) were the most active antimicrobials. Ertapenem activity, unlike amoxicillin-clavulanate or piperacillin-tazobactam, remained virtually unchanged in ESBL (100%) and non-ESBL (98.8%) E. coli producers. Its activity decreased in ESBL-K. pneumoniae (74.7%) but was higher than that of amoxicillin-clavulanate (14.0%) and piperacillin-tazobactam (24.0%). Interestingly, ertapenem susceptibility was maintained in >60% of ESBL isolates that were resistant to amoxicillin-clavulanate, piperacillin-tazobactam or fluoroquinolones. [Conclusions] SMART-Spain results support current guidelines which include ertapenem as empiric treatment in mild-moderate community-acquired IAI, particularly with ESBL producers. These recommendations will need to be updated with the recently introduction of new antimicrobials. [Introducción] El estudio SMART (Study for Monitoring Antimicrobial Resistance Trends) monitoriza la sensibilidad antimicrobiana y las β-lactamasas de espectro extendido (BLEE) en bacilos gramnegativos obtenidos de infecciones intraabdominales (IIA). [Material y Métodos] Se ha analizado la sensibilidad antimicrobiana (microdilución estándar, criterios EUCAST) y las BLEE (detección fenotípica) de 5.343 aislados de IIA en 11 centros del programa SMART-España durante 2011-2015 en comparación con 2002-2010. [Resultados] Escherichia coli, el microorganismo más prevalente, disminuyó significativamente en las IIA de origen comunitario (60,9% 2002-2010 vs. 56,1% 2011-2015, P=0,0003). Fue seguido en prevalencia por Klebsiella pneumoniae que aumentó tanto en IIA comunitaria (8,9% vs. 10,8%, P=0,016) como nosocomial (9,2% vs. 10,8%, P=0,029) y por P. aeruginosa que aumentó en la IIA comunitaria (5,6% vs. 8,0%, P=0,0003). Las BLEE fueron más prevalentes en la IIA nosocomial por K. pneumoniae (16,3%) que por E. coli (9,5%), siendo más frecuentes en pacientes de mayor edad (>60 años). Considerando todas las Enterobacteriaceae, ertapenem (92,3-100%) y amikacina (95,5%-100%) fueron los antimicrobianos más activos. La sensibilidad a ertapenem, al contrario que a amoxicilina-clavulánico o piperacilina-tazobactam, se mantuvo sin cambios en E. coli con (98,8%) y sin BLEE (100%). Su sensibilidad disminuyó en BLEE-K. pneumoniae(74,7%) pero fue mayor que la de amoxicilina-clavulánico (14,0%) o piperacilina-tazobactam (24,0%). Es de resaltar que esta actividad se mantuvo >60% en los aislados con BLEE resistentes a amoxicilina-clavulánico, piperacilina-tazobactam o fluoroquinolonas. [Conclusiones+ El estudio SMART-España sustenta las guías actuales que incluyen al ertapenem como tratamiento empírico en la IIA leve-moderada comunitaria, en particular con BLEE. Estas recomendaciones precisaran actualizarse con la reciente introducción de nuevos antimicrobianos.
- Published
- 2018
10. [Kingella kingae as a common cause of arthritis septic in children]
- Author
-
Illán-Ramos, M, Guillén-Martín, S, Prieto-Tato, L M, Cacho-Calvo, J B, González-Romo, F, Francisco-González, L, and Ramos-Amador, J T
- Subjects
musculoskeletal diseases ,Male ,Arthritis, Infectious ,Neisseriaceae Infections ,Infant ,Osteomyelitis ,Kingella kingae ,Polymerase Chain Reaction ,Body Fluids ,Child, Preschool ,Humans ,Female ,Joints ,Child ,Retrospective Studies - Abstract
Kingella kingae is a common colonizer of the oropharynx in children that may lead to invasive infection, mainly osteoarticular infections. Invasive infections occur almost exclusively in young children, fundamentally fewer than two years old. K. kingae infections in children are probably underdiagnosed due to the difficulty in growing in routine cultures and the absence of systematic realization of molecular techniques to identify it. It is the most common bacteria involved in childhood osteoarticular infections in recent series and increasingly being recognized in Spain. We report our experience on the epidemiological and clinical characteristics of osteoarticular infections in children in recent years.
- Published
- 2018
11. Staphylococcus aureus meningitis in adults: A comparative cohort study of infections caused by meticillin-resistant and meticillin-susceptible strains
- Author
-
Pintado, V., primary, Pazos, R., additional, Jiménez-Mejías, M.E., additional, Rodríguez-Guardado, A., additional, Díaz-Pollán, B., additional, Cabellos, C., additional, García-Lechuz, J.M., additional, Lora-Tamayo, J., additional, Domingo, P., additional, Muñez, E., additional, Domingo, D., additional, González-Romo, F., additional, Lepe-Jiménez, J.A., additional, Rodríguez-Lucas, C., additional, Gil, A., additional, Pelegrín, I., additional, Chaves, F., additional, Pomar, V., additional, Ramos, A., additional, Alarcón, T., additional, and Pérez-Cecilia, E., additional
- Published
- 2019
- Full Text
- View/download PDF
12. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance
- Author
-
Fernández-Ruiz, M., primary, Guinea, J., additional, Lora-Pablos, D., additional, Zaragoza, Ó., additional, Puig-Asensio, M., additional, Almirante, B., additional, Cuenca-Estrella, M., additional, Aguado, J.M., additional, Padilla, B., additional, Muñoz, P., additional, Paño Pardo, J.R., additional, García-Rodríguez, J., additional, Cerrada, C.G., additional, Fortún, J., additional, Martín, P., additional, Gómez, E., additional, Ryan, P., additional, Campelo, C., additional, de los Santos Gil, I., additional, Buendía, V., additional, Gorricho, B.P., additional, Alonso, M., additional, Sanz, F.S., additional, Merino, P., additional, González Romo, F., additional, Gorgolas, M., additional, Gadea, I., additional, Losa, J.E., additional, Delgado-Iribarren, A., additional, Ramos, A., additional, Romero, Y., additional, Romero, I.S., additional, Zaragoza, O., additional, Rodríguez-Baño, J., additional, Suarez, A.I., additional, Loza, A., additional, Aller García, A.I., additional, Martín-Mazuelos, E., additional, Pérez de Pipaón, M.R., additional, Garnacho, J., additional, Ortiz, C., additional, Chávez, M., additional, Maroto, F.L., additional, Salavert, M., additional, Pemán, J., additional, Blanquer, J., additional, Navarro, D., additional, Camarena, J.J., additional, Zaragoza, R., additional, Abril, V., additional, Gimeno, C., additional, Hernández, S., additional, Ezpeleta, G., additional, Bereciartua, E., additional, Hernández Almaraz, J.L., additional, Montejo, M., additional, Rivas, R.A., additional, Ayarza, R., additional, Planes, A.M., additional, Camps, I.R., additional, Mensa, J., additional, Almela, M., additional, Gurgui, M., additional, Sánchez-Reus, F., additional, Martínez-Montauti, J., additional, Sierra, M., additional, Horcajada, J.P., additional, Sorli, L., additional, Gómez, J., additional, Gené, A., additional, Urrea, M., additional, Mularoni, A., additional, Valerio, M., additional, Díaz-Martín, A., additional, and Puchades, F., additional
- Published
- 2017
- Full Text
- View/download PDF
13. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
- Author
-
Rueda, C., primary, Puig-Asensio, M., additional, Guinea, J., additional, Almirante, B., additional, Cuenca-Estrella, M., additional, Zaragoza, O., additional, Padilla, B., additional, Muñoz, P., additional, Paño Pardo, J.R., additional, García-Rodríguez, J., additional, García Cerrada, C., additional, Fortún, J., additional, Martín, P., additional, Gómez, E., additional, Ryan, P., additional, Campelo, C., additional, de los Santos Gil, I., additional, Buendía, V., additional, Gorricho, B.P., additional, Alonso, M., additional, Sanz, F.S., additional, Aguado, J.M., additional, Merino, P., additional, González Romo, F., additional, Gorgolas, M., additional, Gadea, I., additional, Losa, J.E., additional, Delgado-Iribarren, A., additional, Ramos, A., additional, Romero, Y., additional, Sánchez Romero, I., additional, Rodriguez-Baño, J., additional, Isabel Suarez, A., additional, Loza, A., additional, Aller García, A.I., additional, Martín-Mazuelos, E., additional, Pérez de Pipaón, M.R., additional, Garnacho, J., additional, Ortiz, C., additional, Chávez, M., additional, Maroto, F.L., additional, Salavert, M., additional, Pemán, J., additional, Blanquer, J., additional, Navarro, D., additional, Camarena, J.J., additional, Zaragoza, R., additional, Abril, V., additional, Gimeno, C., additional, Hernáez, S., additional, Ezpeleta, G., additional, Bereciartua, E., additional, Hernández Almaraz, J.L., additional, Montejo, M., additional, Rivas, R.A., additional, Ayarza, R., additional, Planes, A.M., additional, Camps, I.R., additional, Mensa, J., additional, Almela, M., additional, Gurgui, M., additional, Sánchez-Reus, F., additional, Martinez-Montauti, J., additional, Sierra, M., additional, Horcajada, J.P., additional, Sorli, L., additional, Gómez, J., additional, Gené, A., additional, Urrea, M., additional, Valerio, M., additional, Díaz-Martín, A., additional, Puchades, F., additional, and Mularoni, A., additional
- Published
- 2017
- Full Text
- View/download PDF
14. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort
- Author
-
López-Cortés, L.E., primary, Almirante, B., additional, Cuenca-Estrella, M., additional, Garnacho-Montero, J., additional, Padilla, B., additional, Puig-Asensio, M., additional, Ruiz-Camps, I., additional, Rodríguez-Baño, J., additional, Muñoz, P., additional, Guinea, J., additional, Paño Pardo, J.R., additional, García-Rodríguez, J., additional, García Cerrada, C., additional, Fortún, J., additional, Martín, P., additional, Gómez, E., additional, Ryan, P., additional, Campelo, C., additional, de los Santos Gil, I., additional, Buendía, V., additional, Pérez Gorricho, B., additional, Alonso, M., additional, Sanz Sanz, F., additional, María Aguado, J., additional, Merino, P., additional, González Romo, F., additional, Gorgolas, M., additional, Gadea, I., additional, Losa, J.E., additional, Delgado-Iribarren, A., additional, Ramos, A., additional, Romero, Y., additional, Sánchez Romero, I., additional, Zaragoza, O., additional, Suarez, A.I., additional, Loza, A., additional, Aller García, A.I., additional, Martín-Mazuelos, E., additional, Pérez de Pipaón, M.R., additional, Garnacho, J., additional, Ortiz, C., additional, Chávez, M., additional, Maroto, F.L., additional, Salavert, M., additional, Pemán, J., additional, Blanquer, J., additional, Navarro, D., additional, Camarena, J.J., additional, Zaragoza, R., additional, Abril, V., additional, Gimeno, C., additional, Hernáez, S., additional, Ezpeleta, G., additional, Bereciartua, E., additional, Hernández Almaraz, J.L., additional, Montejo, M., additional, Rivas, R.A., additional, Ayarza, R., additional, Planes, A.M., additional, Ruiz Camps, I., additional, Mensa, J., additional, Almela, M., additional, Gurgui, M., additional, Sánchez-Reus, F., additional, Martinez-Montauti, J., additional, Sierra, M., additional, Horcajada, J.P., additional, Sorli, L., additional, Gómez, J., additional, Gené, A., additional, Urrea, M., additional, Valerio, M., additional, Díaz-Martín, A., additional, Puchades, F., additional, and Mularoni, A., additional
- Published
- 2016
- Full Text
- View/download PDF
15. Infections in diabetic foot ulcers
- Author
-
Candel González, F.J., primary, Alramadan, M., additional, Matesanz, M., additional, Diaz, A., additional, González-Romo, F., additional, Candel, I., additional, Calle, A., additional, and Picazo, J.J., additional
- Published
- 2003
- Full Text
- View/download PDF
16. [Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions].,Consenso sobre la vacunación anti-neumocócica en el adulto con patología de base
- Author
-
Picazo, J. J., González-Romo, F., Amós García Rojas, Peréz-Trallero, E., Gil Gregorio, P., La Cámara, R., Morató, M. L., Rodríguez, A., Barberán, J., Domínguez Hernández, V., Linares Rufo, M., Jimeno Sanz, I., Portolés, J. M., Sanz Herrero, F., Espinosa Arranz, J., García-Sánchez, V., and Galindo Izquierdo, M.
17. Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among gram-negative organisms recovered during the SMART study in Spain (2011-2015),Evolución de la sensibilidad y de los aislados productores de β-lactamasas de espectro extendido en microorganismos gramnegativos en el estudio SMART en España (2011-2015)
- Author
-
Cantón, R., Loza, E., Aznar, J., Barrón-Adúriz, R., Calvo, J., Castillo, F. J., Cercenado, E., Cisterna, R., González-Romo, F., López-Hontangas, J. L., Suárez-Barrenechea, A. I., Tubau, F., Molloy, B., López-Mendoza, D., Herrero, O., Martínez-Martínez, L., M. Angeles Domínguez, Sáenz, J. L. P., Seral, C., Arcía-Castillo, M., Prieto, J., González-Galán, V., and Pascual, A.
18. Erratum to «Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper» [Arch Bronconeumol. 2024;60(3):161-170].
- Author
-
Redondo E, Rivero-Calle I, Mascarós E, Ocaña D, Jimeno I, Gil Á, Linares M, Onieva-García MÁ, González-Romo F, Yuste J, and Martinón-Torres F
- Published
- 2024
- Full Text
- View/download PDF
19. Fluconazole-resistant Candida parapsilosis: fast detection of the Y132F ERG11p substitution, and a proposed microsatellite genotyping scheme.
- Author
-
Guinea J, Alcoceba E, Padilla E, Ramírez A, De Carolis E, Sanguinetti M, Muñoz-Algarra M, Durán-Valle T, Quiles-Melero I, Merino P, González-Romo F, Sánchez-García A, Gómez-García-de-la-Pedrosa E, Pérez-Ayala A, Mantecón-Vallejo MÁ, Pemán J, Cuétara MS, Zurita ND, García-Esteban C, Martínez-Jiménez MDC, Sánchez Castellano MÁ, Reigadas E, Muñoz P, and Escribano P
- Abstract
Objectives: We propose fast and accurate molecular detection of the Y132F ERG11p substitution directly on pure-cultured Candida parapsilosis isolates. We also assessed a discriminative genotyping scheme to track circulating genotypes., Methods: A total of 223 C. parapsilosis isolates (one patient each) from 20 hospitals, located in Spain and Italy were selected. Isolates were fluconazole-resistant (n = 94; harbouring the Y132F ERG11p substitution [n = 85], the G458S substitution [n = 6], the R398I substitution [n = 2], or the wild-type ERG11 gene sequence) or fluconazole-susceptible (n = 129). Two targeted-A395T-mutation PCR formats (conventional and real-time) were engineered and optimized on fluconazole-susceptible and fluconazole-resistant pure-cultured isolates, thus skipping DNA extraction. Two genotyping schemes were compared: Scheme 1 (CP1, CP4a, CP6, and B markers), and Scheme 2 (6A, 6B, 6C, CP1, CP4a, and CP6 markers)., Results: The screening performed using both PCR formats showed 100% specificity (fluconazole-susceptible isolates; n = 129/129) and sensitivity (Y132F isolates; n = 85/85) values; however, results were available in 3 and 1.5 hours with the conventional and real-time PCR formats, respectively. Overall, Scheme 1 showed higher genetic diversity than Scheme 2, as shown by the number of alleles detected (n = 98; mean 23, range 13-38), the significantly higher observed and expected heterozygosity, and the probability of identity index (2.5 × 10
-6 ). Scheme 2 markers did not provide further genotypic discrimination of Y132F fluconazole-resistant genotypes., Conclusion: Both proposed PCR formats allow us to speed up the accurate detection of substitution Y132F ERG11p in C. parapsilosis isolates with 100% specificity and sensitivity. In addition, we recommend CP1, CP4a, CP6, and B microsatellite markers for genotyping fluconazole-resistant isolates., (Copyright © 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
20. [Usefulness of plasma procalcitonin as a predictor of bacteremia due to Gram-negative microorganisms].
- Author
-
Salinas-Botrán A, Humanes-Navarro AM, and González-Romo F
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Predictive Value of Tests, Adult, Procalcitonin blood, Bacteremia diagnosis, Bacteremia blood, Gram-Negative Bacterial Infections blood, Gram-Negative Bacterial Infections diagnosis, Biomarkers blood
- Published
- 2024
- Full Text
- View/download PDF
21. Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy: Description of azole-resistance profiles associated with the Y132F ERG11p substitution.
- Author
-
Mesquida A, Alcoceba E, Padilla E, Ramírez A, Merino P, González-Romo F, De Carolis E, Sanguinetti M, Mantecón-Vallejo MLÁ, Muñoz-Algarra M, Durán-Valle T, Pérez-Ayala A, Gómez-García-de-la-Pedrosa E, Del Carmen Martínez-Jiménez M, Sánchez-Castellano MÁ, Quiles-Melero I, Cuétara MS, Sánchez-García A, Muñoz P, Escribano P, and Guinea J
- Subjects
- Humans, Candida parapsilosis genetics, Cities, Voriconazole pharmacology, Amphotericin B, Anidulafungin, Micafungin, Italy, Hospitals, Genotype, Azoles pharmacology, Fluconazole pharmacology, Triazoles, Nitriles, Triterpenes, Glycosides, Pyridines
- Abstract
Background: Fluconazole-resistant Candida parapsilosis is a matter of concern., Objectives: To describe fluconazole-resistant C. parapsilosis genotypes circulating across hospitals in Spain and Rome and to study their azole-resistance profile associated with ERG11p substitutions., Patients/methods: We selected fluconazole-resistant C. parapsilosis isolates (n = 528 from 2019 to 2023; MIC ≥8 mg/L according to EUCAST) from patients admitted to 13 hospitals located in five Spanish cities and Rome. Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp susceptibility., Results: Of the 53 genotypes found, 49 harboured the Y132F substitution, five of which were dominating city-specific genotypes involving almost half the isolates. Another genotype involved isolates harbouring the G458S substitution. Finally, we found two genotypes with the wild-type ERG11 gene sequence and one with the R398I substitution. All isolates were fully susceptible/wild-type to amphotericin B, anidulafungin, micafungin and ibrexafungerp. The azole-resistance patterns found were: voriconazole-resistant (74.1%) or voriconazole-intermediate (25.2%), posaconazole-resistant (10%) and isavuconazole non-wild-type (47.5%). Fluconazole-resistant and voriconazole non-wild-type isolates were likely to harbour substitution Y132F if posaconazole was wild type; however, if posaconazole was non-wild type, substitution G458S was indicated if isavuconazole MIC was >0.125 mg/L or substitution Y132F if isavuconazole MIC was ≤0.125 mg/L., Conclusions: We detected a recent clonal spread of fluconazole-resistant C. parapsilosis across some cities in Spain, mostly driven by dominating city-specific genotypes, which involved a large number of isolates harbouring the Y132F ERG11p substitution. Isolates harbouring substitution Y132F can be suspected because they are non-susceptible to voriconazole and rarely posaconazole-resistant., (© 2024 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
22. Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper.
- Author
-
Redondo E, Rivero-Calle I, Mascarós E, Ocaña D, Jimeno I, Gil Á, Linares M, Onieva-García MÁ, González-Romo F, Yuste J, and Martinón-Torres F
- Subjects
- Humans, Middle Aged, Aged, Vaccination, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Tract Infections
- Abstract
Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in adults, particularly older adults and those with underlying medical conditions. Vaccination has emerged as a potential key strategy to prevent RSV-related morbidity and mortality. This Neumoexperts Prevention (NEP) Group scientific paper aims to provide an evidence-based positioning and RSV vaccination recommendations for adult patients. We review the current literature on RSV burden and vaccine development and availability, emphasising the importance of vaccination in the adult population. According to our interpretation of the data, RSV vaccines should be part of the adult immunisation programme, and an age-based strategy should be preferred over targeting high-risk groups. The effectiveness and efficiency of this practice will depend on the duration of protection and the need for annual or more spaced doses. Our recommendations should help healthcare professionals formulate guidelines and implement effective vaccination programmes for adult patients at risk of RSV infection now that specific vaccines are available., (Copyright © 2024 The Authors. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Antifungal resistance in Candida spp within the intra-abdominal cavity: study of resistance acquisition in patients with serial isolates.
- Author
-
Díaz-García J, Machado M, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, Gómez-García de la Pedrosa E, González-Romo F, Merino P, Cuétara MS, García-Esteban C, Quiles-Melero I, Zurita ND, Muñoz-Algarra M, Durán-Valle MT, Martínez-Quintero GA, Sánchez-García A, Muñoz P, Escribano P, and Guinea J
- Subjects
- Humans, Fluconazole, Echinocandins pharmacology, Amphotericin B, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida glabrata, Microbial Sensitivity Tests, Drug Resistance, Fungal, Antifungal Agents pharmacology, Candida
- Abstract
Objectives: Antifungal susceptibility testing is mostly conducted on blood-cultured Candida spp isolates. Because the intra-abdominal cavity has been highlighted as a hidden echinocandin-resistant C. glabrata reservoir, we assessed whether testing sequential isolates from a given patient might increase the chances of detecting antifungal resistance., Methods: Intra-abdominal initial and sequential isolates from the same species from patients included in the CANDIdaemia in MADrid study (January 2019 to June 2022) were studied. We assessed antifungal susceptibility to amphotericin B, azoles, anidulafungin, micafungin, and ibrexafungerp using European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology and molecularly characterized resistant isolates., Results: We collected 308 isolates (C. albicans [n = 179/308; 58.1%], C. glabrata [n = 101/308; 32.8%], C. tropicalis [n = 17/308; 5.5%], and C. parapsilosis [n = 11/308; 3.6%]) from 112 patients distributed as incident (n = 125/308) and sequential (n = 183/308). Per patient resistance rates of fluconazole (13.4% [15/112] vs. 8% [9/112]); 5.4% proportions difference (95% CI, -2.7% to 13.5%, p 0.09) and echinocandins (8.9% [10/112] vs. 1.8% [2/112]); 7.1% proportions difference (95% CI; 1.2-12.9%; p 0.01) were higher when considering all available isolates than only incident isolates. Resistance was detected in 18 of 112 patients and would have been overlooked in 11 of 18 (61.1%) patients if only incident isolates had been studied. Of the patients who harboured fluconazole or echinocandin-resistant isolates, 14 of 15 and 8 of 10 had received or were receiving fluconazole or echinocandins, respectively., Discussion: Testing sequential Candida isolates from intra-abdominal samples is required to detect antifungal resistance, particularly to echinocandins, in patients whose incident isolates turned out to be susceptible. Furthermore, patients with echinocandin-resistant infections had frequently used echinocandins and had common secondary resistance acquisition., (Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Non-Candida isolates from blood cultures and intra-abdominal samples: data derived from a multicentre prospective study conducted in Madrid.
- Author
-
Díaz-García J, Gómez A, Machado M, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, Gómez-García de la Pedrosa E, González-Romo F, Cuétara MS, García-Esteban C, Quiles-Melero I, Zurita ND, Muñoz-Algarra M, Durán-Valle MT, Sánchez-García A, Muñoz P, Escribano P, and Guinea J
- Subjects
- Humans, Prospective Studies, Echinocandins, Microbial Sensitivity Tests, Drug Resistance, Fungal, Blood Culture, Antifungal Agents therapeutic use
- Published
- 2023
- Full Text
- View/download PDF
25. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020.
- Author
-
García-Fernández S, Calvo J, Cercenado E, Suárez-Barrenechea AI, Fernández-Billón M, Castillo FJ, Gálvez-Benítez L, Tubau F, Figueroa Cerón RE, Hernández-Cabezas A, González Romo F, Fariñas MC, Gómez M, Díaz-Regañón J, and Cantón R
- Subjects
- Humans, Spain epidemiology, Anti-Bacterial Agents pharmacology, Imipenem pharmacology, beta-Lactamase Inhibitors pharmacology, Microbial Sensitivity Tests, Pseudomonas aeruginosa, Pseudomonas Infections
- Abstract
Objective: To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 - 2020., Methods: Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints., Results: In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam., Conclusions: Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients' location (ICU or non-ICU scenarios)., (©The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).)
- Published
- 2023
- Full Text
- View/download PDF
26. Correction: Díaz-García et al. Candida Genotyping of Blood Culture Isolates from Patients Admitted to 16 Hospitals in Madrid: Genotype Spreading during the COVID-19 Pandemic Driven by Fluconazole-Resistant C. parapsilosis . J. Fungi 2022, 8 , 1228.
- Author
-
Díaz-García J, Gómez A, Machado M, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, de la Pedrosa EG, González-Romo F, Cuétara MS, García-Esteban C, Quiles-Melero I, Zurita ND, Algarra MM, Durán-Valle MT, Sánchez-García A, Muñoz P, Escribano P, Guinea J, and On Behalf Of The Candimad Study
- Abstract
In the original publication [...].
- Published
- 2023
- Full Text
- View/download PDF
27. Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group.
- Author
-
Redondo E, Rivero-Calle I, Mascarós E, Ocaña D, Jimeno I, Gil Á, Díaz-Maroto JL, Linares M, Onieva-García MÁ, González-Romo F, Yuste J, and Martinón-Torres F
- Abstract
In the adult population, community-acquired pneumonia (CAP) is a serious disease that is responsible for high morbidity and mortality rates, being frequently associated with multidrug resistant pathogens. The aim of this review is to update a practical immunization prevention guideline for CAP in Spain caused by prevalent respiratory pathogens, based on the available scientific evidence through extensive bibliographic review and expert opinion. The emergence of COVID-19 as an additional etiological cause of CAP, together with the rapid changes in the availability of vaccines and recommendations against SARS-CoV-2, justifies the need for an update. In addition, new conjugate vaccines of broader spectrum against pneumococcus, existing vaccines targeting influenza and pertussis or upcoming vaccines against respiratory syncytial virus (RSV) will be very useful prophylactic tools to diminish the burden of CAP and all of its derived complications. In this manuscript, we provide practical recommendations for adult vaccination against the pathogens mentioned above, including their contribution against antibiotic resistance. This guide is intended for the individual perspective of protection and not for vaccination policies, as we do not pretend to interfere with the official recommendations of any country. The use of vaccines is a realistic approach to fight these infections and ameliorate the impact of antimicrobial resistance. All of the recently available scientific evidence included in this review gives support to the indications established in this practical guide to reinforce the dissemination and implementation of these recommendations in routine clinical practice.
- Published
- 2023
- Full Text
- View/download PDF
28. Candida Genotyping of Blood Culture Isolates from Patients Admitted to 16 Hospitals in Madrid: Genotype Spreading during the COVID-19 Pandemic Driven by Fluconazole-Resistant C. parapsilosis .
- Author
-
Díaz-García J, Gómez A, Machado M, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, de la Pedrosa EG, González-Romo F, Cuétara MS, García-Esteban C, Quiles-Melero I, Zurita ND, Algarra MM, Durán-Valle MT, Sánchez-García A, Muñoz P, Escribano P, Guinea J, and On Behalf Of The Candimad Study Group
- Abstract
Background: Candidaemia and invasive candidiasis are typically hospital-acquired. Genotyping isolates from patients admitted to different hospitals may be helpful in tracking clones spreading across hospitals, especially those showing antifungal resistance., Methods: We characterized Candida clusters by studying Candida isolates ( C. albicans , n = 1041; C. parapsilosis , n = 354, and C. tropicalis , n = 125) from blood cultures (53.8%) and intra-abdominal samples (46.2%) collected as part of the CANDIMAD ( Candida in Madrid) study in Madrid (2019-2021). Species-specific microsatellite markers were used to define the genotypes of Candida spp. found in a single patient (singleton) or several patients (cluster) from a single hospital (intra-hospital cluster) or different hospitals (widespread cluster)., Results: We found 83 clusters, of which 20 were intra-hospital, 49 were widespread, and 14 were intra-hospital and widespread. Some intra-hospital clusters were first detected before the onset of the COVID-19 pandemic, but the number of clusters increased during the pandemic, especially for C. parapsilosis . The proportion of widespread clusters was significantly higher for genotypes found in both compartments than those exclusively found in either the blood cultures or intra-abdominal samples. Most C. albicans- and C. tropicalis -resistant genotypes were singleton and presented exclusively in either blood cultures or intra-abdominal samples. Fluconazole-resistant C. parapsilosis isolates belonged to intra-hospital clusters harboring either the Y132F or G458S ERG11p substitutions; the dominant genotype was also widespread., Conclusions: the number of clusters-and patients involved-increased during the COVID-19 pandemic mainly due to the emergence of fluconazole-resistant C. parapsilosis genotypes.
- Published
- 2022
- Full Text
- View/download PDF
29. Global Emergence of Resistance to Fluconazole and Voriconazole in Candida parapsilosis in Tertiary Hospitals in Spain During the COVID-19 Pandemic.
- Author
-
Trevijano-Contador N, Torres-Cano A, Carballo-González C, Puig-Asensio M, Martín-Gómez MT, Jiménez-Martínez E, Romero D, Nuvials FX, Olmos-Arenas R, Moretó-Castellsagué MC, Fernández-Delgado L, Rodríguez-Sevilla G, Aguilar-Sánchez MM, Ayats-Ardite J, Ardanuy-Tisaire C, Sanchez-Romero I, Muñoz-Algarra M, Merino-Amador P, González-Romo F, Megías-Lobón G, García-Campos JA, Mantecón-Vallejo MÁ, Alcoceba E, Escribano P, Guinea J, Durán-Valle MT, Fraile-Torres AM, Roiz-Mesones MP, Lara-Plaza I, de Ayala AP, Simón-Sacristán M, Collazos-Blanco A, Nebreda-Mayoral T, March-Roselló G, Alcázar-Fuoli L, and Zaragoza O
- Abstract
Background: Candida parapsilosis is a frequent cause of candidemia worldwide. Its incidence is associated with the use of medical implants, such as central venous catheters or parenteral nutrition. This species has reduced susceptibility to echinocandins, and it is susceptible to polyenes and azoles. Multiple outbreaks caused by fluconazole-nonsusceptible strains have been reported recently. A similar trend has been observed among the C. parapsilosis isolates received in the last 2 years at the Spanish Mycology Reference Laboratory., Methods: Yeast were identified by molecular biology, and antifungal susceptibility testing was performed using the European Committee on Antimicrobial Susceptibility Testing protocol. The ERG11 gene was sequenced to identify resistance mechanisms, and strain typing was carried out by microsatellite analysis., Results: We examined the susceptibility profile of 1315 C. parapsilosis isolates available at our reference laboratory between 2000 and 2021, noticing an increase in the number of isolates with acquired resistance to fluconazole, and voriconazole has increased in at least 8 different Spanish hospitals in 2020-2021. From 121 recorded clones, 3 were identified as the most prevalent in Spain (clone 10 in Catalonia and clone 96 in Castilla-Leon and Madrid, whereas clone 67 was found in 2 geographically unrelated regions, Cantabria and the Balearic Islands)., Conclusions: Our data suggest that concurrently with the coronavirus disease 2019 pandemic, a selection of fluconazole-resistant C. parapsilosis isolates has occurred in Spain, and the expansion of specific clones has been noted across centers. Further research is needed to determine the factors that underlie the successful expansion of these clones and their potential genetic relatedness., Competing Interests: Potential conflicts of interest. All authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
30. Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris.
- Author
-
Díaz-García J, Gómez A, Machado M, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, Gómez-García De La Pedrosa E, González-Romo F, Cuétara MS, García-Esteban C, Quiles-Melero I, Zurita ND, Muñoz-Algarra M, Durán-Valle MT, Sánchez-García A, Muñoz P, Escribano P, and Guinea J
- Subjects
- Humans, Fluconazole, Candida, Antifungal Agents pharmacology, Candida auris, Microbial Sensitivity Tests, Drug Resistance, Fungal, Echinocandins pharmacology, Candida parapsilosis
- Abstract
Objectives: We prospectively monitored the epidemiology and antifungal susceptibility of Candida spp. from blood cultures and intra-abdominal samples in patients admitted to hospitals in the Madrid area., Methods: Between 2019 and 2021, we prospectively collected incident isolates [one per species, patient and compartment (blood cultures versus intra-abdominal samples)] from patients admitted to any of 16 hospitals located in Madrid. We studied the antifungal susceptibilities to amphotericin B, triazoles, micafungin, anidulafungin and ibrexafungerp following the EUCAST E.Def 7.3.2 procedure., Results: A total of 2107 Candida spp. isolates (1895 patients) from blood cultures (51.7%) and intra-abdominal samples were collected. Candida albicans, the Candida glabrata complex, the Candida parapsilosis complex, Candida tropicalis and Candida krusei accounted for 96.9% of the isolates; in contrast, Candida auris was undetected. Fluconazole resistance in Candida spp. was higher in blood cultures than in intra-abdominal samples (9.1% versus 8.2%; P > 0.05), especially for the C. parapsilosis complex (16.6% versus 3.6%, P < 0.05), whereas echinocandin resistance tended to be lower in blood cultures (0.5% versus 1.0%; P > 0.05). Resistance rates have risen, particularly for fluconazole in blood culture isolates, which increased sharply in 2021. Ibrexafungerp showed in vitro activity against most isolates. Species distributions and resistance rates varied among hospitals., Conclusions: Whereas no C. auris isolates were detected, fluconazole-resistant C. parapsilosis isolates have been spreading across the region and this has pulled up the rate of fluconazole resistance. In contrast, the rate of echinocandin resistance continues to be low., (© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
31. Seroprevalence of anti-SARS-CoV-2 IgG antibodies: relationship with COVID-19 diagnosis, symptoms, smoking, and method of transmission.
- Author
-
Bühler KM, Echeverry-Alzate V, Calleja-Conde J, Durán-González P, Segovia-Rodriguez L, Morales-García JA, Pérez-Wiesner M, Cables-Chozas D, de Fonseca FR, Delgado-Iribarren A, Merino-Amador P, González-Romo F, Giné E, and López-Moreno JA
- Abstract
Aims: The study of SARS-CoV-2 antibodies in the population is a crucial step towards overcoming the COVID-19 pandemic. Seroepidemiological studies allow an estimation of the number of people who have been exposed to the virus, as well as the number of people who are still susceptible to infection., Methods: In total, 13 560 people from Arganda del Rey, Madrid (Spain) were assessed between January and March 2021 for the presence of IgG antibodies, using rapid tests and histories of symptoms compatible with COVID-19., Results: 24.2% of the participants had IgG antibodies and 9% had a positive COVID-19 diagnosis. Loss of smell/taste was the most discriminating symptom of the disease. The main transmitters of infection were found to be household members. Unexpectedly, in smokers, the incidence of positive COVID-19 diagnoses was significantly lower. Additionally, it was found that there was a discrepancy between COVID-19 diagnosis and the presence of IgG antibodies., Conclusions: Rapid anti-IgG tests are less reliable in detecting SARS-CoV-2 infection at an individual level, but are functional in estimating SARS-CoV-2 infection rates at an epidemiological level. The loss of smell/taste is a potential indicator for establishing COVID-19 infection., Competing Interests: The authors declare no commercial or financial conflicts of interest., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
32. Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution.
- Author
-
Díaz-García J, Gómez A, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, Gómez-García de la Pedrosa E, González-Romo F, Merino-Amador P, Cuétara MS, García-Esteban C, Quiles-Melero I, Zurita ND, Muñoz-Algarra M, Sánchez-Romero I, Durán-Valle MT, Sánchez-García A, Alcoceba E, Muñoz P, Escribano P, and Guinea J
- Subjects
- Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Drug Resistance, Fungal genetics, Genotype, Hospitals, Humans, Microbial Sensitivity Tests, Spain epidemiology, Candida parapsilosis genetics, Fluconazole pharmacology
- Abstract
We have been monitoring the antifungal resistance in Candida parapsilosis isolates collected from inpatients at Madrid metropolitan area hospitals for the last 3 years. The study aimed to elucidate the presence of fluconazole-resistant C. parapsilosis genotypes in Madrid. From January 2019 to December 2021, a total of 354 C. parapsilosis isolates ( n = 346 patients) from blood (76.6%) or intraabdominal samples were collected and genotyped using species-specific microsatellite markers. Antifungal susceptibilities to amphotericin B, the triazoles, micafungin, anidulafungin, and ibrexafungerp were performed according to EUCAST E.Def 7.3.2; the ERG11 gene was sequenced in fluconazole-resistant isolates. A total of 13.6% ( n = 48/354) isolates (one per patient) were found to be resistant to fluconazole and non-wild-type to voriconazole but fully susceptible to ibrexafungerp. Resistant isolates were mostly sourced from blood ( n = 45/48, 93.8%) and were detected in five hospitals. Two hospitals accounted for a high proportion of resistant isolates ( n = 41/48). Resistant isolates harbored either the Y132F ERG11p amino acid substitution ( n = 43) or the G458S substitution ( n = 5). Isolates harboring the Y132F substitution clustered into a clonal complex involving three genotypes (one genotype accounted for n = 39/43 isolates) that were found in four hospitals. Isolates harboring the G458S substitution clustered into another genotype found in a fifth hospital. C. parapsilosis genotypes demonstrating resistance to fluconazole have been spreading across hospitals in Madrid, Spain. Over the last 3 years, the frequency of isolation of such isolates and the number of hospitals affected is on the rise.
- Published
- 2022
- Full Text
- View/download PDF
33. Clinitest rapid COVID-19 antigen test for the diagnosis of SARS-CoV-2 infection: A multicenter evaluation study.
- Author
-
Merino-Amador P, González-Donapetry P, Domínguez-Fernández M, González-Romo F, Sánchez-Castellano MÁ, Seoane-Estevez A, Delgado-Iribarren A, García J, Bou G, Cuenca-Estrella M, and Oteo-Iglesias J
- Subjects
- Antigens, Viral, Citric Acid, Copper Sulfate, Humans, Prospective Studies, Reproducibility of Results, Sensitivity and Specificity, Sodium Bicarbonate, COVID-19, SARS-CoV-2
- Abstract
Objectives: RT-PCR assay is the reference method for diagnosis of COVID-19, but it is also a laborious and time-consuming technic, limiting the availability of testing. Rapid antigen-detection tests are faster and less expensive; however, the reliability of these tests must be validated before they can be used widely. The objective of this study was to determine the performance of the Clinitest Rapid COVID-19 Antigen Test (ClinitestRT) (SIEMENS) for SARS-CoV-2 in nasopharyngeal swab specimens., Methods: This prospective multicenter study was carried out in three Spanish university hospitals including individuals with clinical symptoms or epidemiological criteria for COVID-19. Only individuals with ≤7 days from the onset of symptoms or from exposure to a confirmed case of COVID-19 were included. Two nasopharyngeal samples were taken to perform the ClinitestRT, as a point-of-care test, and a diagnostic RT-PCR test., Results: Overall sensitivity and specificity for the ClinitestRT among the 450 patients studied were 93.3% (CI 95%: 89.7-96.8) and 99.2% (CI 95%: 97.2-99.8), respectively. Sensitivity in participants with ≤5 days of the clinical course was 93.6% (CI 95%: 89.2-96.3), and in participants who had a C
T < 25 for the RT-PCR test was 98.4% (CI 95%: 94.5-99.6). Agreement between techniques was 96.7% (kappa score: 0.93; CI 95%: 0.90-0.97)., Conclusions: The ClinitestRT provides good clinical performance, with more reliable results for patients with a higher viral load. The results must be interpreted based on the local epidemiological context., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
34. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
- Author
-
Cantón R, Loza E, Arcay RM, Cercenado E, Castillo FJ, Cisterna R, Gálvez-Benítez L, González Romo F, Hernández-Cabezas A, Rodríguez-Lozano J, Suárez-Barrenechea AI, Tubau F, Díaz-Regañón J, and López-Mendoza D
- Subjects
- Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Cephalosporins pharmacology, Drug Resistance, Bacterial, Escherichia coli, Humans, Microbial Sensitivity Tests, Spain epidemiology, Tazobactam, Pseudomonas Infections drug therapy, Pseudomonas Infections epidemiology, Pseudomonas aeruginosa
- Abstract
Objective: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study., Methods: The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases., Results: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam., Conclusions: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases., (©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).)
- Published
- 2021
- Full Text
- View/download PDF
35. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection.
- Author
-
Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N, Cilla G, Hernáez-Crespo S, Díaz-de Tuesta JL, Gual-de Torrella A, González-Romo F, Escribano P, Sánchez-Castellano MÁ, Sota-Busselo M, Delgado-Iribarren A, García J, Cantón R, Muñoz P, Folgueira MD, Cuenca-Estrella M, and Oteo-Iglesias J
- Abstract
Objectives: The standard RT-PCR assay for coronavirus disease 2019 (COVID-19) is laborious and time-consuming, limiting testing availability. Rapid antigen-detection tests are faster and less expensive; however, the reliability of these tests must be validated before they can be used widely. The objective of this study was to determine the performance of the Panbio™ COVID-19 Ag Rapid Test Device (PanbioRT) (Abbott) in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swab specimens., Methods: This prospective multicentre study was carried out in ten Spanish university hospitals and included individuals with clinical symptoms or epidemiological criteria of COVID-19. Only individuals with ≤7 days from the onset of symptoms or from exposure to a confirmed case of COVID-19 were included. Two nasopharyngeal samples were taken to perform the PanbioRT as a point-of-care test and a diagnostic RT-PCR test., Results: Among the 958 patients studied, 325 (90.5%) had true-positive results. The overall sensitivity and specificity for the PanbioRT were 90.5% (95%CI 87.5-93.6) and 98.8% (95%CI 98-99.7), respectively. Sensitivity in participants who had a threshold cycle (C
T ) < 25 for the RT-PCR test was 99.5% (95%CI 98.4-100), and in participants with ≤5 days of the clinical course it was 91.8% (95%CI 88.8-94.8). Agreement between techniques was 95.7% (κ score 0.90; 95%CI 0.88-0.93)., Conclusions: The PanbioRT performs well clinically, with even more reliable results for patients with a shorter clinical course of the disease or a higher viral load. The results must be interpreted based on the local epidemiological context., (Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
36. Linezolid for therapy of Staphylococcus aureus meningitis: a cohort study of 26 patients.
- Author
-
Pintado V, Pazos R, Jiménez-Mejías ME, Rodríguez-Guardado A, Díaz-Pollán B, Cabellos C, García-Lechuz JM, Lora-Tamayo J, Domingo P, Muñez E, Domingo D, González-Romo F, Lepe-Jiménez JA, Rodríguez-Lucas C, Valencia E, Pelegrín I, Chaves F, Pomar V, Ramos A, Alarcón T, and Pérez-Cecilia E
- Subjects
- Adult, Anti-Bacterial Agents therapeutic use, Female, Humans, Male, Methicillin-Resistant Staphylococcus aureus, Middle Aged, Retrospective Studies, Spain, Staphylococcus aureus, Cross Infection drug therapy, Linezolid therapeutic use, Meningitis, Bacterial drug therapy, Staphylococcal Infections drug therapy
- Abstract
Background: Linezolid has good penetration to the meninges and could be an alternative for treatment of Staphylococcus aureus meningitis. We assessed the efficacy and safety of linezolid therapy for this infection., Methods: Retrospective multicenter cohort study of 26 adults treated with linezolid, derived from a cohort of 350 cases of S. aureus meningitis diagnosed at 11 university hospitals in Spain (1981-2015)., Results: There were 15 males (58%) and mean age was 47.3 years. Meningitis was postoperative in 21 (81%) patients. The infection was nosocomial in 23 (88%) cases, and caused by methicillin-resistant S. aureus in 15 cases and methicillin-susceptible S. aureus in 11. Linezolid was given as empirical therapy in 10 cases, as directed therapy in 10, and due to failure of vancomycin in 6. Monotherapy was given to 16 (62%) patients. Median duration of linezolid therapy was 17 days (IQR 12-22 days) with a daily dose of 1,200 mg in all cases. The clinical response rate to linezolid was 69% (18/26) and microbiological response was observed in 14 of 15 cases evaluated (93%). Overall 30-day mortality was 23% and was directly associated with infection in most cases. When compared with the patients of the cohort, no significant difference in mortality was observed between patients receiving linezolid or vancomycin for therapy of methicillin-resistant S. aureus meningitis (9% vs. 20%; p = .16) nor between patients receiving linezolid or cloxacillin for therapy of methicillin-susceptible S. aureus meningitis (20% vs 14%; p = .68). Adverse events appeared in 14% (3/22) of patients, but linezolid was discontinued in only one patient., Conclusions: Linezolid appears to be effective and safe for therapy of S. aureus meningitis. Our findings showed that linezolid may be considered an adequate alternative to other antimicrobials in meningitis caused by S. aureus.
- Published
- 2020
- Full Text
- View/download PDF
37. Genotypic and Phenotypic Characteristics of Staphylococcus aureus Prosthetic Joint Infections: Insight on the Pathogenesis and Prognosis of a Multicenter Prospective Cohort.
- Author
-
Muñoz-Gallego I, Viedma E, Esteban J, Mancheño-Losa M, García-Cañete J, Blanco-García A, Rico A, García-Perea A, Ruiz Garbajosa P, Escudero-Sánchez R, Sánchez Somolinos M, Marín Arriaza M, Romanyk J, Barbero JM, Arribi Vilela A, González Romo F, Pérez-Jorge C, M Arana D, Monereo A, Domingo D, Cordero J, Sánchez Romero MI, García Viejo MÁ, Lora-Tamayo J, and Chaves F
- Abstract
Background: Staphylococcus aureus is the leading cause of prosthetic joint infection (PJI). Beyond the antibiogram, little attention has been paid to the influence of deep microbiological characteristics on patient prognosis. Our aim was to investigate whether microbiological genotypic and phenotypic features have a significant influence on infection pathogenesis and patient outcome., Methods: A prospective multicenter study was performed, including all S. aureus PJIs (2016-2017). Clinical data and phenotypic ( agr functionality, β-hemolysis, biofilm formation) and genotypic characteristics of the strains were collected. Biofilm susceptibility to antimicrobials was investigated (minimal biofilm eradication concentration [MBEC] assay)., Results: Eighty-eight patients (39.8% men, age 74.7 ± 14.1 years) were included. Forty-five had early postoperative infections (EPIs), 21 had chronic infections (CPIs), and 19 had hematogenous infections (HIs). Twenty (22.7%) were caused by methicillin-resistant S. aureus . High genotypic diversity was observed, including 16 clonal complexes (CCs), with CC5 being the most frequent (30.7%). agr activity was greater in EPI than CPI (55.6% vs 28.6%; P = .041). Strains causing EPI were phenotypically and genotypically similar, regardless of symptom duration. Treatment failure (36.5%) occurred less frequently among cases treated with implant removal. In cases treated with debridement and implant retention, there were fewer failures among those who received combination therapy with rifampin. No genotypic or phenotypic characteristics predicted failure, except vancomycin minimal inhibitory concentration ≥1.5 mg/L (23.1% failure vs 3.4%; P = .044). MBEC
50 was >128 mg/L for all antibiotics tested and showed no association with prognosis., Conclusions: S. aureus with different genotypic backgrounds is capable of causing PJI, showing slight differences in clinical presentation and pathogenesis. No major microbiological characteristics were observed to influence the outcome, including MBEC., (© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)- Published
- 2020
- Full Text
- View/download PDF
38. Saezia sanguinis gen. nov., sp. nov., a Betaproteobacteria member of order Burkholderiales , isolated from human blood.
- Author
-
Medina-Pascual MJ, Monzón S, Villalón P, Cuesta I, González-Romo F, and Valdezate S
- Subjects
- Aged, 80 and over, Bacterial Typing Techniques, Base Composition, Betaproteobacteria isolation & purification, DNA, Bacterial genetics, Fatty Acids chemistry, Humans, Male, Phospholipids chemistry, RNA, Ribosomal, 16S genetics, Sequence Analysis, DNA, Spain, Ubiquinone chemistry, Betaproteobacteria classification, Blood microbiology, Phylogeny
- Abstract
The taxonomic position of an unknown bacterial strain designated CNM695-12, isolated from the blood of an immunocompromised subject, was investigated via phenotypic, chemotaxonomic, genotypic and genomic analyses. Bacterial cells were determined to be Gram-stain-negative bacilli, aerobic, non-motile and non-spore-forming. The strain showed catalase activity but no oxidase activity. Optimal growth occurred at 37 °C, pH 7 and with 0-1 % NaCl. C
16 : 0 , summed feature 8 (comprising C18 : 1 ω7 c / C18:1 ω6 c ), and C18 : 1 ω9 c were the most abundant fatty acids, and ubiquinone 8 was the major respiratory quinone. The polar lipids present included phosphatidylglycerol, phosphatidylethanolamine and other aminophospholipids. The 16S rRNA gene sequence showed approximately 93.5 % similarity to those of different species with validly published names within the order Burkholderiales (e.g. Leptothrix mobilis Feox-1T , Aquabacterium commune B8T , Aquabacterium citratiphilum B4T and Schlegelella thermodepolymerans K14T ). Phylogenetic analyses based on 16S rRNA gene sequences and concatenated alignments including the sequences for 107 essential proteins, revealed the strain to form a novel lineage close to members of the family Comamonadaceae . The highest average nucleotide identity and average amino acid identity values were obtained with Schlegelella thermodepolymerans K14T (69.6 and 55.7 % respectively). The genome, with a size of 3.35 Mb, had a DNA G+C content of 52.4 mol% and encoded 3056 predicted genes, 3 rRNA, 1 transfer-messengerRNA and 51 tRNA. Strain CNM695-12 thus represents a novel species belonging to a novel genus within the order Burkholderiales , for which the name Saezia sanguinis gen. nov., sp. nov. is proposed. The type strain is CNM695-12T (=DSM 104959T =CECT 9208T ).- Published
- 2020
- Full Text
- View/download PDF
39. Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).
- Author
-
Cantón R, Loza E, Aznar J, Castillo FJ, Cercenado E, Fraile-Ribot PA, González-Romo F, López-Hontangas JL, Rodríguez-Lozano J, Suárez-Barrenechea AI, Tubau F, Díaz-Regañón J, and López-Mendoza D
- Subjects
- Adult, Aged, Cross Infection drug therapy, Drug Resistance, Bacterial drug effects, Drug Resistance, Bacterial genetics, Female, Gram-Negative Bacterial Infections epidemiology, Humans, Intraabdominal Infections epidemiology, Male, Microbial Sensitivity Tests, Middle Aged, Population Surveillance, Spain epidemiology, Urinary Tract Infections epidemiology, beta-Lactamases genetics, beta-Lactamases metabolism, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Gram-Negative Bacteria drug effects, Gram-Negative Bacterial Infections drug therapy, Gram-Negative Bacterial Infections microbiology, Intraabdominal Infections drug therapy, Intraabdominal Infections microbiology, Urinary Tract Infections drug therapy, Urinary Tract Infections microbiology
- Abstract
Objective: Continuous antimicrobial resistance surveillance is recommended by Public Health authorities. We up-dated data from the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain., Methods: The antimicrobial susceptibility data and extended-spectrum beta-lactamase (ESBL) production in isolates recovered from intra-abdominal (IAI) (n=1,429) and urinary tract (UTI) (n=937) infections during the 2016- 2017 SMART study in 10 Spanish hospitals were analysed., Results: Escherichia coli was the most frequently microorganism isolated (48.3% and 53.7%) followed by Klebsiella spp. (11.5% and 21.9%) in IAIs and UTIs, respectively. Figures for Pseudomonas aeruginosa were 9.0% and 6.1%, being more frequently recovered from patients with nosocomial infections. Overall, 9.9% (IAI) and 14.0% (UTI) of E. coli, Klebsiella spp. and Proteus mirabilis isolates were ESBL-producers, being Klebsiella pneumoniae (34.5%) from UTI of nosocomial origin the most frequent. ESBL-producers were higher in patients >60 years in both IAIs and UTIs. As in previous years, amikacin (96.3%-100% susceptibility), ertapenem (84.2%-100%) and imipenem (70.3%- 100%) were the most active antimicrobials tested among Enterobacterales species. The activity of amoxicillin-clavulanic, piperacillin-tazobactam, and ciprofloxacin susceptibility was lower, particularly among ESBL-producers. Ertapenem susceptibility (88.9%-100%) was retained in ESBL-E. coli isolates that were resistant to these antimicrobials but decreased (28.6%-100%) in similar isolates of K. pneumoniae., Conclusions: Continuous antimicrobial resistance surveillance from the SMART study reveals overall maintenance of ESBL-producers in Spain, although with higher presence in isolates from UTIs than from IAIs. Moreover, ertapenem activity was high in E. coli irrespective of ESBL production but decreased in K. pneumoniae, particularly among ESBL-producers., (©The Author 2019. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).)
- Published
- 2019
40. [Kingella kingae as a common cause of arthritis septic in children].
- Author
-
Illán-Ramos M, Guillén-Martín S, Prieto-Tato LM, Cacho-Calvo JB, González-Romo F, Francisco-González L, and Ramos-Amador JT
- Subjects
- Body Fluids microbiology, Child, Child, Preschool, Female, Humans, Infant, Joints, Male, Osteomyelitis microbiology, Polymerase Chain Reaction, Retrospective Studies, Arthritis, Infectious etiology, Arthritis, Infectious microbiology, Kingella kingae, Neisseriaceae Infections complications, Neisseriaceae Infections microbiology
- Abstract
Objective: Kingella kingae is a common colonizer of the oropharynx in children that may lead to invasive infection, mainly osteoarticular infections. Invasive infections occur almost exclusively in young children, fundamentally fewer than two years old. K. kingae infections in children are probably underdiagnosed due to the difficulty in growing in routine cultures and the absence of systematic realization of molecular techniques to identify it. It is the most common bacteria involved in childhood osteoarticular infections in recent series and increasingly being recognized in Spain. We report our experience on the epidemiological and clinical characteristics of osteoarticular infections in children in recent years., Methods: Retrospective analysis of septic arthritis by K. kingae identified by PCR in joint fluid in children during 2010-2016. Epidemiological, clinical and laboratory characteristics are presented., Results: Five arthritis by K. kingae were identified, all of them in ≤6 years old children. Median leukocytes, CRP and ESR were 12950 leukocytes/μL, 4.84 mg/dL and 58 mm/h respectively, and 61,322 leukocytes /μL in joint fluid. All patients evolved favorably., Conclusions: Osteoarticular infections by K. kingae in children usually present low increase of inflammatory markers despite being invasive infections. The development of PCR in sterile samples has greatly improved the diagnostic yield of K. kingae infections improving the management of osteoarthritis in children., (©The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).)
- Published
- 2018
41. Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among Gram-negative organisms recovered during the SMART study in Spain (2011-2015).
- Author
-
Cantón R, Loza E, Aznar J, Barrón-Adúriz R, Calvo J, Castillo FJ, Cercenado E, Cisterna R, González-Romo F, López-Hontangas JL, Suárez-Barrenechea AI, Tubau F, Molloy B, and López-Mendoza D
- Subjects
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Cross Infection microbiology, Drug Combinations, Ertapenem, Escherichia coli drug effects, Female, Gram-Negative Bacterial Infections drug therapy, Humans, Klebsiella pneumoniae drug effects, Male, Microbial Sensitivity Tests, Middle Aged, Prevalence, Spain epidemiology, beta-Lactamases analysis, beta-Lactams pharmacology, beta-Lactams therapeutic use, Gram-Negative Bacteria drug effects, Gram-Negative Bacterial Infections microbiology, beta-Lactamases metabolism
- Abstract
Objective: The SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study monitors antimicrobial susceptibility and extended spectrum β-lactamases (ESBLs) in Gram-negative bacilli recovered from intra-abdominal infections (IAI)., Methods: Antimicrobial susceptibility of 5,343 isolates from IAI recovered in 11 centres during the 2011-2015 SMART-Spain program was analysed by standard microdilution (EUCAST criteria) and compared with that from 2002-2010. ESBLs were phenotypically detected., Results: Escherichia coli, the most common isolate, significantly decreased in community acquired IAI (60.9% 2002-2010 vs. 56.1% 2011-2015, P=0.0003). It was followed in prevalence by Klebsiella pneumoniae that increased both in the community (8.9% vs. 10.8%, P=0.016) and nosocomial (9.2% vs. 10.8%, P=0.029) IAI and P. aeruginosa, which significantly increased in community acquired IAI (5.6% vs. 8.0%, P=0.0003). ESBLs were more prevalent in K. pneumoniae (16.3%) than in E. coli (9.5%) of nosocomial origin and were more frequently isolated from elderly patients (>60 years). Considering all Enterobacteriaceae, ertapenem (92.3-100%) and amikacin (95.5%-100%) were the most active antimicrobials. Ertapenem activity, unlike amoxicillin-clavulanate or piperacillin-tazobactam, remained virtually unchanged in ESBL (100%) and non-ESBL (98.8%) E. coli producers. Its activity decreased in ESBL-K. pneumoniae (74.7%) but was higher than that of amoxicillin-clavulanate (14.0%) and piperacillin-tazobactam (24.0%). Interestingly, ertapenem susceptibility was maintained in >60% of ESBL isolates that were resistant to amoxicillin-clavulanate, piperacillin-tazobactam or fluoroquinolones., Conclusions: SMART-Spain results support current guidelines which include ertapenem as empiric treatment in mild-moderate community-acquired IAI, particularly with ESBL producers. These recommendations will need to be updated with the recently introduction of new antimicrobials., (© The Author 2018. Published by Sociedad Española de Quimioterapia.)
- Published
- 2018
42. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study.
- Author
-
Muñoz P, Vena A, Machado M, Gioia F, Martínez-Jiménez MC, Gómez E, Origüen J, Orellana MÁ, López-Medrano F, Fernández-Ruiz M, Merino P, González-Romo F, Frías I, Pérez-Granda MJ, Aguado JM, Fortún J, and Bouza E
- Subjects
- Adult, Aged, Antibodies, Fungal blood, Blood Culture, Candidiasis diagnosis, Candidiasis, Invasive diagnosis, Female, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, beta-Glucans blood, Antifungal Agents therapeutic use, Candidiasis diagnostic imaging, Candidiasis drug therapy, Candidiasis, Invasive diagnostic imaging, Candidiasis, Invasive drug therapy, Magnetic Resonance Imaging methods
- Abstract
Objectives: We assessed the potential role of T2Candida MR (T2MR) and serological biomarkers [β-d-glucan (BDG) or Candida albicans germ tube antibodies (CAGTA)], alone or in combination with standard cultures, for identifying patients with suspected invasive candidiasis (IC), who may benefit from maintaining antifungal therapy., Methods: Prospective observational multicentre study including all adult patients receiving empirical antifungal therapy for suspected IC, from January to June 2017. CAGTA, BDG and T2MR were determined at baseline and at +2 and +4 days after enrolment. Primary endpoint was the diagnostic value of CAGTA, BDG and T2MR, alone or in combination with standard culture, to predict diagnosis of IC and/or mortality in the first 7 days after starting antifungal therapy (poor outcome)., Results: Overall, 14/49 patients (28.6%) had a poor outcome (7 died within the first 7 days of antifungal therapy, whereas 7 ended with a diagnosis of IC). CAGTA [3/14 (21.4%) versus 8/35 (22.9%), P = 1] and BDG [8/14 (57.1%) versus 17/35 (48.6%), P = 0.75] results were similar in poor- and good-outcome patients. Conversely, a positive T2MR was associated with a higher risk of poor outcome [5/14 (35.7%) versus 0/35 (0.0%) P = 0.0001]. Specificity and positive predictive value of a positive T2MR for predicting poor outcome were both 100%, with a negative predictive value of 79.6%. After testing the combinations of biomarkers/standard cultures and T2MR/standard cultures, the combination of T2MR/standard cultures showed a high capacity to discriminate patients with poor outcome from those with good clinical evolution., Conclusions: T2MR may be of significant utility to identify patients who may benefit from maintaining antifungal therapy.
- Published
- 2018
- Full Text
- View/download PDF
43. Why Should We Recommend Pneumococcal Vaccine in Patients With Chronic Heart Diseases?
- Author
-
González-Romo F and Barrios V
- Subjects
- Adolescent, Adult, Aged, Chronic Disease, Female, Heart Diseases mortality, Humans, Male, Middle Aged, Pneumococcal Infections complications, Pneumococcal Infections mortality, Risk Factors, Spain epidemiology, Survival Rate trends, Young Adult, Heart Diseases complications, Pneumococcal Infections prevention & control, Pneumococcal Vaccines pharmacology, Streptococcus pneumoniae immunology, Vaccination methods
- Published
- 2018
- Full Text
- View/download PDF
44. [Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. 2017 Update].
- Author
-
González-Romo F, Picazo JJ, García Rojas A, Labrador Horrillo M, Barrios V, Magro MC, Gil Gregorio P, de la Cámara R, Rodríguez A, Barberán J, Botía Martínez F, Linares Rufo M, Jimeno Sanz I, Portolés JM, Sanz Herrero F, Espinosa Arranz J, García-Sánchez V, Galindo Izquierdo M, and Mascarós E
- Subjects
- Adult, Aged, Child, Child, Preschool, Consensus, Humans, Pneumonia, Pneumococcal prevention & control, Streptococcus pneumoniae, Vaccination, Pneumococcal Infections prevention & control, Pneumococcal Vaccines
- Abstract
Invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) represent an important health problem among aging adults and those with certain underlying pathologies and some diseases, especially immunosuppressed and some immunocompetent subjects, who are more susceptible to infections and present greater severity and worse evolution. Among the strategies to prevent IPD and PP, vaccination has its place, although vaccination coverage in this group is lower than desirable. Nowadays, there are 2 vaccines available for adults. Polysacharide vaccine (PPV23), used in patients aged 2 and older since decades ago, includes a greater number of serotypes (23), but it does not generate immune memory, antibody levels decrease with time, causes an immune tolerance phenomenon, and have no effect on nasopharyngeal colonization. PCV13 can be used from children 6 weeks of age to elderly and generates an immune response more powerful than PPV23 against most of the 13 serotypes included in it. In the year 2013 the 16 most directly related to groups of risk of presenting IPD publised a series of vaccine recommendations based on scientific evidence regarding anti-pneumococcal vaccination in adults with underlying pathologies and special conditions. A commitment was made about updating it if new scientific evidence became available. We present an exhaustive revised document focusing mainly in recommendation by age in which some more Scientific Societies have been involved.
- Published
- 2017
45. [Successful treatment of Abiotrophia defective endophthalmitis].
- Author
-
Valverde-Mejías A, González-Romo F, Saez JA, Torres-Imaz R, García-Feijoo J, and Merino P
- Subjects
- Aged, Female, Humans, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Vision Disorders etiology, Vision Disorders therapy, Abiotrophia, Anti-Bacterial Agents therapeutic use, Endophthalmitis drug therapy, Endophthalmitis microbiology, Gram-Positive Bacterial Infections drug therapy, Gram-Positive Bacterial Infections microbiology
- Published
- 2016
46. [Development of new vaccines].
- Author
-
González-Romo F and Picazo JJ
- Subjects
- Adjuvants, Immunologic, Communicable Diseases, Emerging immunology, Communicable Diseases, Emerging prevention & control, Epitopes immunology, Humans, Public Opinion, Vaccination psychology, Vaccination trends, Vaccines, Subunit, Vaccines, Synthetic, Vaccines adverse effects, Vaccines immunology
- Abstract
Recent and important advances in the fields of immunology, genomics, functional genomics, immunogenetics, immunogenomics, bioinformatics, microbiology, genetic engineering, systems biology, synthetic biochemistry, proteomics, metabolomics and nanotechnology, among others, have led to new approaches in the development of vaccines. The better identification of ideal epitopes, the strengthening of the immune response due to new adjuvants, and the search of new routes of vaccine administration, are good examples of advances that are already a reality and that will favour the development of more vaccines, their use in indicated population groups, or its production at a lower cost. There are currently more than 130 vaccines are under development against the more wished (malaria or HIV), difficult to get (CMV or RSV), severe re-emerging (Dengue or Ebola), increasing importance (Chagas disease or Leishmania), and nosocomial emerging (Clostridium difficile or Staphylococcus aureus) infectious diseases., (Copyright © 2015. Published by Elsevier España, S.L.U.)
- Published
- 2015
- Full Text
- View/download PDF
47. Recommendations for vaccination against pneumococcus in kidney patients in Spain.
- Author
-
Portolés-Pérez J, Marques-Vidas M, Picazo JJ, González-Romo F, García-Rojas A, Pérez-Trallero E, Gil-Gregorio P, de la Cámara R, Morató ML, Rodríguez A, Barberán J, Domínguez-Hernández V, Linares-Rufo M, Jimeno-Sanz I, Sanz-Herrero F, Espinosa-Arranz J, García-Sánchez V, Galindo-Izquierdo M, and Martínez-Castelao A
- Subjects
- Humans, Pneumococcal Infections complications, Pneumococcal Infections epidemiology, Practice Guidelines as Topic, Risk Factors, Spain, Pneumococcal Infections prevention & control, Pneumococcal Vaccines, Renal Insufficiency, Chronic complications, Vaccination
- Abstract
Unlabelled: Invasive pneumococcal disease (IPD) is a serious problem in some risk groups: patients with stage 4 and 5 chronic kidney disease, stage 3 CKD undergoing immunosuppressive treatment, nephrotic syndrome or diabetes. These individuals are more susceptible to infections and more prone to suffering more severe and worsening symptoms. Vaccination is one of the strategies for preventing IPD, although vaccination coverage in this group at present is lower than desired. Currently, there are two vaccinations for adults. The polysaccharide vaccine (PPSV23), used for decades in patients over the age of 2, includes most serotypes (23), but it does not generate immune memory, causing the immune tolerance phenomenon and it does not act on nasopharyngeal colonisation. The conjugate vaccine (VNC13) can be used from infancy until adulthood (advice in patients over 18 years old received approval from the European Medicines Agency in July 2013) and generates a more powerful immune response than PPSV23 against the majority of the 13 serotypes that it includes. The 16 scientific societies most directly associated with the groups at risk of IPD have discussed and drafted a series of vaccination recommendations based on scientific evidence related to pneumococcal vaccination in adults with underlying conditions and pathologies, which are the subject of the document “, Consensus: Pneumococcal vaccination in adults with underlying pathology”. This text sets out the vaccination recommendations for the chronic kidney disease population.
- Published
- 2014
- Full Text
- View/download PDF
48. [Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions].
- Author
-
Picazo JJ, González-Romo F, García Rojas A, Peréz-Trallero E, Gil Gregorio P, de la Cámara R, Morató ML, Rodríguez A, Barberán J, Domínguez Hernández V, Linares Rufo M, Jimeno Sanz I, Portolés JM, Sanz Herrero F, Espinosa Arranz J, García-Sánchez V, and Galindo Izquierdo M
- Subjects
- Adult, Consensus, Cost-Benefit Analysis, Drug Resistance, Bacterial, Humans, Incidence, Odds Ratio, Pneumococcal Infections complications, Pneumococcal Infections economics, Pneumococcal Infections epidemiology, Pneumococcal Infections mortality, Pneumococcal Vaccines economics, Polysaccharides, Bacterial immunology, Risk Factors, Streptococcus pneumoniae drug effects, Vaccines, Conjugate therapeutic use, Pneumococcal Infections prevention & control, Pneumococcal Vaccines therapeutic use, Vaccination
- Published
- 2013
49. [Whooping cough in Spain. Current epidemiology, prevention and control strategies. Recommendations by the Pertussis Working Group].
- Author
-
Campins M, Moreno-Pérez D, Gil-de Miguel A, González-Romo F, Moraga-Llop FA, Arístegui-Fernández J, Goncé-Mellgren A, Bayas JM, and Salleras-Sanmartí L
- Subjects
- Adolescent, Adult, Bordetella pertussis immunology, Child, Child, Preschool, Female, Health Personnel, Humans, Immunization Schedule, Immunization, Secondary, Incidence, Infant, Infant, Newborn, Male, Pertussis Vaccine, Pregnancy, Pregnancy Complications, Infectious prevention & control, Spain epidemiology, Vaccination, Whooping Cough diagnosis, Whooping Cough drug therapy, Diphtheria-Tetanus Vaccine administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Whooping Cough epidemiology, Whooping Cough prevention & control
- Abstract
A large increase of pertussis incidence has been observed in recent years in countries with high vaccination coverage. Outbreaks of pertussis are increasingly being reported. The age presentation has a bipolar distribution: infants younger 6months that have not initiated or completed a vaccination schedule, and adolescents and adults, due to the lost of natural or vaccine immunity over time. These epidemiological changes justify the need to adopt new vaccination strategies in order to protect young infants and to reduce pertussis incidence in all age groups. Adolescents and adults immunization must be a priority. In the first group, strategy is easy to implement, and with a very low additional cost (to replace dT vaccine by dTap one). Adult vaccination may be more difficult to implement; dT vaccine decennial booster should be replaced by dTap. The immunization of household contacts of newborn infants (cocooning) is the strategy that has a most important impact on infant pertussis. Recently, pregnant women vaccination (after 20weeks of gestation) has been recommended in some countries as the most effective way to protect the newborn., (Copyright © 2012 Elsevier España, S.L. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
50. [Consensus document on vaccination against influenza in health care workers].
- Author
-
Picazo JJ, Alonso LM, Arístegui J, Bayas JM, Sanz J, Del Amo P, Cobos JL, Rodríguez-Salazar J, Sánchez-Pastor M, de la Cámara R, Carratalá J, Cañada JL, González-Del Castillo J, Aldaz P, Pérez-Escanilla F, Barberán J, Rodríguez A, Vigil-Escribano D, Espinosa-Arranz J, Blanquer J, and González-Romo F
- Subjects
- Consensus, Guidelines as Topic, Humans, Influenza Vaccines, Spain epidemiology, Vaccination ethics, Health Personnel ethics, Influenza, Human prevention & control, Vaccination standards
- Abstract
Health care workers (HCW) are included each year among risk groups for vaccination against influenza. However, vaccination coverage among this group in our country is very low, not exceeding 25%. Convinced that one of the best tools to increase this coverage among professionals in our country are the scientific evidence, 19 scientific societies and associations professionals bringing together health professionals more directly related to influenza as an health problem, and the General Nursing Council, met to discuss and develop this consensus document in order to inform HCW about the appropriateness of their vaccination against influenza and the benefits that flow from it for themselves, for their patients and for the rest of the population. This recommendation is based on 3 pillars: argument of necessity, ethics and exemplary.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.